{
    "nct_id": "NCT04642365",
    "official_title": "An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors",
    "inclusion_criteria": "- Diagnosis of advanced and/or metastatic solid tumors who have progressed on a standard therapy, are intolerant to standard of care (SoC), and/or and non-amenable to SoC.\n\nParticipants whose tumors have known sensitizing mutations must have experienced disease progression (during or after treatment) or intolerance to treatment with a respective targeted therapy.\n\n* Measurable disease according to RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Able to provide the most recent archival tumor tissue samples.\n* Adequate cardiovascular, haematological, liver and renal function.\n* Participants on therapeutic anticoagulation must be on a stable anticoagulant regimen.\n* Women of Childbearing Potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods.\n* Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy, lactation, or breastfeeding.\n* Known hypersensitivity to any of the components of RO7296682 and atezolizumab, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.\n* History or clinical evidence of central nervous system (CNS) primary tumors or metastases.\n* Participants with another invasive malignancy in the last two years.\n* Participants with known active or uncontrolled infection.\n* Positive HIV test at screening.\n* Positive for Hepatitis B and C.\n* Vaccination with live vaccines within 28 days prior to C1D1.\n* Major surgical procedure or significant traumatic injury within 28 days prior to first RO7296682 and atezolizumab infusion.\n* Participants with wound healing complications.\n* Dementia or altered mental status that would prohibit informed consent.\n* History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or DRESS (drug rash with eosinophilia and systemic symptoms).\n* Active or history of autoimmune disease or immune deficiency.\n* Prior treatment with CPIs (e.g. anti-CTLA4, anti-PD1, anti-PDL1), immunomodulatory monoclonal antibodies (mAbs) and/or mAb-derived therapies (approved or investigational) is approved.\n* Treatment with standard radiotherapy, any chemotherapeutic agent, targeted therapy or treatment with any other investigational drug (defined as treatment for which there is currently no regulatory authority-approved indication) within 28 days or 5 half-lives of the drug (whichever is shorter), prior to the first RO7296882 administration on C1D1.\n* Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy (for which no wash out period is required).",
    "miscellaneous_criteria": ""
}